I-A2 Biotherapeutics, Inc., inkampani ye-biotechnology egxile kunyango lwamathumba aqinileyo, ibhengeze namhlanje ukuba idatha ephambili ye-preclinical enxulumene neqonga layo lonyango lweseli ye-TMod ™ ipapashwe kwiSayensi yokuGuqulela uNyango kunye neJenali ye-ImmunoTherapy yoMhlaza. Unyango lwe-Tmod™ lwenzelwe izigulana ezinomhlaza ezinamathumba anokucinywa kofuzo oluthile, kwaye uvavanyo lwemfuzo luvumela ukuchongwa kwangaphambili kwezigulana ezinokuxhamla kunyango olunjalo. Unyango lwe-Tmod ™ lusebenzisa ucimo olunjalo ngokutshabalalisa amathumba ngelixa usindisa iiseli eziqhelekileyo, ezinokuthi zibonelele ngendlela entsha ekhuselekileyo nesebenzayo yokunyanga umhlaza wethumba eliqinileyo.
"La maphepha mabini abonisa umzimba omkhulu we-preclinical in vitro kunye nobungqina be-vivo obuxhasa umsebenzi oqinileyo, okhethiweyo wenkqubo ye-Tmod ™, indlela entsha yonyango lomhlaza olujongana nengxaki ephambili ye-oncology - amandla amayeza omhlaza ukwahlula phakathi kwethumba kunye neeseli eziqhelekileyo,” utshilo uGqr. Alexander Kamb, iGosa eliyiNtloko lezeNzululwazi kwi-A2 Bio.
Iphepha elapapashwa nge-2 kaMatshi ka-2022 kwiSayensi yokuGuqulela uNyango (Sandberg et al., "Unyango lweseli eyenzelwe ukujolisa kwi-antigen ye-CEA ngokukhuselekileyo kwizigulana ezikhethiweyo ezinamathumba aqinileyo") ichaza umviwa wezonyango ojoliswe kumathumba aqinileyo ekholoni kunye nezinye. UGqr. Han Xu, uSekela Mongameli weTekhnoloji yoNyango kwi-A1 Bio kunye nombhali ophezulu ephepheni, uthe: "Idatha yethu yangaphambili ibonisa ukuba eli yeza lisekelwe kwiseli liya kuba namandla ekliniki. Ibenchmark yonyango esebenzayo ejoliswe kwi-CEA, kodwa ngaphandle kwetyhefu.
Iphepha elapapashwa nge-28 kaJanuwari, ngo-2022 kwiJenali ye-ImmunoTherapy yoMhlaza (Tokatlian et al., "Unyango lweseli ye-Mesothelin-specific CAR-T olubandakanya indlela yokhuseleko lwe-HLA-gated ngokukhetha ukubulala iiseli zethumba") ibonisa usetyenziso olunokubakho lwe-Tmod. Iiseli ze-T kumhlaza wemiphunga kunye namanye amathumba aqinileyo. UGqr. Agi Hamburger, uSekela Mongameli wezokuFunyaniswa kweZiyobisi kunye nombhali ophezulu, wathi: “Inpapasho yethu ayichazi nje kuphela iimpawu zethemba elitsha elivuyisayo labaguli abanomhlaza wemiphunga kodwa ikwaqaqambisa ukuguquguquka okuchukumisayo kweqonga lethu leTmod™, iqonga esilifumanayo. ithemba linokwandiswa ukwenza unyango lwezinye izigulana ezinomhlaza kwixesha elizayo. ”
INTO ONOKUYITHATHA KWELI NQAKU:
- “These two papers present a large body of preclinical in vitro and in vivo evidence that supports the robust, highly selective function of the Tmod™ system, a new approach to cancer therapy that addresses head-on the central problem of oncology –.
- “Our publication not only describes the properties of an exciting new prospect for lung cancer patients but also highlights the impressive modularity of our Tmod™ platform, a platform that we hope can be extended to create therapies for many other cancer patients in the future.
- , “A cell therapy designed to target the CEA antigen safely in selected patients with solid tumors”) describes a clinical candidate directed at solid tumors of the colon and other organs which is currently advancing toward Phase 1.
